Developing the Ce and La pair as companion positron emission tomography diagnostic isotopes for Ac and Th radiotherapeutics.

Developing targeted α-therapies has the potential to transform how diseases are treated. In these interventions, targeting vectors are labelled with α-emitting radioisotopes that deliver destructive radiation discretely to diseased cells while simultaneously sparing the surrounding healthy tissue. Widespread implementation requires advances in non-invasive imaging technologies that rapidly assay therapeutics.

A reverse U/Th radionuclide generator for targeted alpha therapy applications.

Purpose: Thorium-226 (half-life 30.6 m) is a radionuclide of interest for use in targeted alpha therapy applications. Due to its short half-life, Th must be provided through a radionuclide generator system from its parent U (20.

Production of Pa by proton irradiation of Th at the LANL isotope production facility: Precursor of U for targeted alpha therapy.

Uranium-230 (t = 20.8 d) is an alpha-emitting radionuclide that has potential application in targeted alpha therapy (TAT) of cancer. Its parent isotope Pa (t = 17.

Large-Scale Production of Te and Sb for Radiopharmaceutical Applications.

Radionuclides find widespread use in medical technologies for treating and diagnosing disease. Among successful and emerging radiotherapeutics, Sb has unique potential in targeted therapeutic applications for low-energy electron-emitting isotopes. Unfortunately, developing Sb-based drugs has been slow in comparison to other radionuclides, primarily due to limited accessibility.

Separation of Protactinium Employing Sulfur-Based Extraction Chromatographic Resins.

Protactinium-230 ( t = 17.4 d) is the parent isotope of U ( t = 20.8 d), a radionuclide of interest for targeted alpha therapy (TAT).